University Library
  • Login
A gateway to Melbourne's research publications
Minerva Access is the University's Institutional Repository. It aims to collect, preserve, and showcase the intellectual output of staff and students of the University of Melbourne for a global audience.
View Item 
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Melbourne Medical School
  • Medical Education
  • Medical Education - Research Publications
  • View Item
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Melbourne Medical School
  • Medical Education
  • Medical Education - Research Publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

    Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer

    Thumbnail
    Download
    Published version (309.5Kb)

    Citations
    Scopus
    Web of Science
    Altmetric
    16
    17
    Author
    de Boer, SM; Wortman, BG; Bosse, T; Powell, ME; Singh, N; Hollema, H; Wilson, G; Chowdhury, MN; Mileshkin, L; Pyman, J; ...
    Date
    2018-02-01
    Source Title
    Annals of Oncology
    Publisher
    OXFORD UNIV PRESS
    University of Melbourne Author/s
    Mileshkin, Linda; Pyman, Jan
    Affiliation
    Medical Education
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    de Boer, S. M., Wortman, B. G., Bosse, T., Powell, M. E., Singh, N., Hollema, H., Wilson, G., Chowdhury, M. N., Mileshkin, L., Pyman, J., Katsaros, D., Carinelli, S., Fyles, A., McLachlin, C. M., Haie-Meder, C., Duvillard, P., Nout, R. A., Verhoeven-Adema, K. W., Putter, H. ,... Smit, V. T. H. B. M. (2018). Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer. ANNALS OF ONCOLOGY, 29 (2), pp.424-430. https://doi.org/10.1093/annonc/mdx753.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/253209
    DOI
    10.1093/annonc/mdx753
    Abstract
    Background: In the PORTEC-3 trial, women with high-risk endometrial cancer (HR-EC) were randomised to receive pelvic radiotherapy (RT) with or without concurrent and adjuvant chemotherapy (two cycles of cisplatin 50 mg/m2 in weeks 1 and 4 of RT, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2). Pathology review was required before patient enrolment. The aim of this analysis was to evaluate the role of central pathology review before randomisation. Patients and methods: A total of 1295 cases underwent pathology review to confirm HR-EC in the Netherlands (n = 395) and the UK (n = 900), and for 1226/1295 (95%) matching review and original reports were available. In total, 329 of these patients were enrolled in the PORTEC-3 trial: 145 in the Netherlands and 184 in the UK, comprising 48% of the total PORTEC-3 cohort of 686 participants. Areas of discrepancies were evaluated, and inter-observer agreement between original and review opinion was evaluated by calculating the kappa value (κ). Results: In the 1226 pathology reviews, 6356 selected items were evaluable for both original and review pathology. In 43% of cases at least one pathology item changed after review. For 102 patients (8%), this discrepancy led to ineligibility for the PORTEC-3 trial, most frequently due to differences in the assessment of histological type (34%), endocervical stromal involvement (27%) and histological grade (19%). Lowest inter-observer agreement was found for histological type (κ = 0.72), lymph-vascular space invasion (κ = 0.72) and histological grade (κ = 0.70). Conclusion: Central pathology review by expert gynaeco-pathologists changed histological type, grade or other items in 43% of women with HR-EC, leading to ineligibility for the PORTEC-3 trial in 8%. Upfront pathology review is essential to ensure enrolment of the target trial-population, and to avoid over- or undertreatment, especially when treatment modalities with substantial toxicity are involved. This study is registered with ISRCTN (ISRCTN14387080, www.controlled-trials.com) and with ClinicalTrials.gov (NCT00411138).

    Export Reference in RIS Format     

    Endnote

    • Click on "Export Reference in RIS Format" and choose "open with... Endnote".

    Refworks

    • Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References


    Collections
    • Minerva Elements Records [45770]
    • Medical Education - Research Publications [497]
    Minerva AccessDepositing Your Work (for University of Melbourne Staff and Students)NewsFAQs

    BrowseCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    My AccountLoginRegister
    StatisticsMost Popular ItemsStatistics by CountryMost Popular Authors